Press Releases

What if cancer cells are using a signaling shortcut we’ve been missing? Scientists uncovered a mechanism in a key cell-to-cell communication system—insight that could point to more effective therapies.

Utah’s $33 million investment fuels AI, advanced computing, and secure data innovation—strengthening health research and discovery statewide through leadership at the University of Utah and Huntsman Cancer Institute.

The first three patients have been treated in an early-stage clinical trial of a new radiopharmaceutical medicine at Huntsman Cancer Institute, marking an important step in developing new cancer therapies.

Researchers developed a chip-based platform, “μPharma,” that rapidly predicts drug response through AI analysis for children with T-ALL, potentially enabling clinicians to make faster, personalized treatment decisions.

Three executive leaders describe how they see Huntsman Cancer Institute innovating cancer care and research in 2026.

A Huntsman Cancer Institute researcher evaluated a noninvasive skin imaging technology that accurately discriminates between common moles and melanoma, potentially enhancing melanoma screening while reducing the need for unnecessary biopsies.

Advancing detection of prostate cancer, a new imaging drug targets PSMA—a protein marking cancer cells—helping physicians identify disease earlier and guiding patients toward timely, confident treatment decisions.